IRIS
PINATO, David James
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 4.061
EU - Europa 3.709
NA - Nord America 3.590
SA - Sud America 605
AF - Africa 277
Continente sconosciuto - Info sul continente non disponibili 3
OC - Oceania 3
Totale 12.248
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.431
SG - Singapore 1.881
IE - Irlanda 1.236
HK - Hong Kong 980
BR - Brasile 479
RU - Federazione Russa 474
CN - Cina 448
IT - Italia 402
SE - Svezia 364
DE - Germania 354
VN - Vietnam 222
UA - Ucraina 208
BJ - Benin 206
FR - Francia 146
KR - Corea 138
GB - Regno Unito 135
IN - India 110
CA - Canada 95
FI - Finlandia 93
AT - Austria 87
PL - Polonia 52
AR - Argentina 49
BD - Bangladesh 45
MX - Messico 44
JP - Giappone 43
ID - Indonesia 42
ES - Italia 36
NL - Olanda 35
ZA - Sudafrica 32
IR - Iran 30
LT - Lituania 26
TR - Turchia 26
CO - Colombia 17
EC - Ecuador 15
IQ - Iraq 15
CZ - Repubblica Ceca 14
BE - Belgio 13
CH - Svizzera 13
MA - Marocco 12
PY - Paraguay 11
CL - Cile 10
VE - Venezuela 10
PK - Pakistan 9
SA - Arabia Saudita 8
UZ - Uzbekistan 8
IL - Israele 6
JO - Giordania 6
PH - Filippine 6
UY - Uruguay 6
AE - Emirati Arabi Uniti 5
DO - Repubblica Dominicana 5
EG - Egitto 5
BG - Bulgaria 4
BO - Bolivia 4
DZ - Algeria 4
KE - Kenya 4
NP - Nepal 4
PE - Perù 4
TT - Trinidad e Tobago 4
BH - Bahrain 3
ET - Etiopia 3
EU - Europa 3
KZ - Kazakistan 3
LV - Lettonia 3
MY - Malesia 3
OM - Oman 3
PS - Palestinian Territory 3
PT - Portogallo 3
TN - Tunisia 3
AM - Armenia 2
BA - Bosnia-Erzegovina 2
BF - Burkina Faso 2
BN - Brunei Darussalam 2
GT - Guatemala 2
HN - Honduras 2
JM - Giamaica 2
KH - Cambogia 2
LB - Libano 2
LI - Liechtenstein 2
AI - Anguilla 1
AU - Australia 1
AZ - Azerbaigian 1
BB - Barbados 1
CD - Congo 1
CI - Costa d'Avorio 1
CR - Costa Rica 1
CY - Cipro 1
DM - Dominica 1
GE - Georgia 1
GR - Grecia 1
LA - Repubblica Popolare Democratica del Laos 1
LU - Lussemburgo 1
MD - Moldavia 1
ML - Mali 1
MT - Malta 1
MU - Mauritius 1
NG - Nigeria 1
NI - Nicaragua 1
NR - Nauru 1
PF - Polinesia Francese 1
Totale 12.242
Salva come PNG Salva come JPEG
Città #
Dublin 1.234
Hong Kong 976
Singapore 644
Ashburn 389
Beijing 253
Los Angeles 218
Cotonou 206
Lawrence 149
Moscow 149
Princeton 149
Jacksonville 141
Wilmington 139
Seoul 137
Buffalo 130
San Mateo 125
Chandler 113
New York 91
Ho Chi Minh City 79
Novara 66
Dallas 62
São Paulo 59
Nuremberg 57
Dearborn 55
Helsinki 54
Hanoi 52
Brooklyn 50
Redondo Beach 48
Santa Clara 48
Piemonte 46
Vienna 46
Munich 41
Warsaw 39
Ann Arbor 38
Assago 36
Chennai 36
Frankfurt am Main 36
Denver 35
Tokyo 35
Falkenstein 32
Stockholm 32
Toronto 32
Chicago 31
Boardman 28
London 28
Milan 26
Montreal 26
Orem 26
Houston 25
Phoenix 25
Poplar 25
Boston 24
Johannesburg 24
Turin 24
Vercelli 24
Andover 23
Strasbourg 22
Amsterdam 20
Atlanta 20
Jakarta 20
Bremen 18
Manchester 17
Mexico City 17
Mumbai 16
Zanjan 16
Ankara 15
Haiphong 14
Norwalk 14
Roubaix 14
Dhaka 13
San Francisco 13
Brussels 12
Pleasantville 12
Tianjin 12
Turku 12
Woodbridge 11
Belo Horizonte 10
West Jordan 10
Brasília 9
Querétaro 9
Raleigh 9
Ribeirão Preto 9
Rio de Janeiro 9
Rome 9
Bexley 8
City of London 8
Dong Ket 8
Elk Grove Village 8
New Delhi 8
Seattle 8
Thái Bình 8
Zurich 8
Brno 7
Calgary 7
Genoa 7
Nanjing 7
Porto Alegre 7
Charlotte 6
Cleveland 6
Da Nang 6
Düsseldorf 6
Totale 7.221
Salva come PNG Salva come JPEG
Nome #
Society for Immunotherapy of Cancer (SITC) recommendations on intratumoral immunotherapy clinical trials (IICT): from premalignant to metastatic disease 159
On-target sorafenib toxicity predicts improved survival in hepatocellular carcinoma: a multi-centre, prospective study 134
Validation of the Hepatoma Arterial Embolization Prognostic Score in European and Asian Populations and Proposed Modification. 116
Integration of the cancer-related inflammatory response as a stratifying biomarker of survival in hepatocellular carcinoma treated with sorafenib 109
Long-term sequelae are highly prevalent one year after hospitalization for severe COVID-19 107
Evaluation of the red cell distribution width as a biomarker of early mortality in hepatocellular carcinoma 100
Combined sequential use of HAP and ART scores to predict survival outcome and treatment failure following chemoembolization in hepatocellular carcinoma: A multi-center comparative study 99
Identification of mutations in circulating cell-free tumour DNA as a biomarker in hepatocellular carcinoma 95
Presenting features and early mortality from SARS-CoV-2 infection in cancer patients during the initial stage of the COVID-19 pandemic in Europe 95
Prevalence and impact of COVID-19 sequelae on treatment pathways and survival of patients with cancer who recovered from SARS-Cov-2 infection: results from the OnCovid registry. 94
Determinants of long COVID among adults hospitalized for SARS-CoV-2 infection: A prospective cohort study 92
The ALBI grade provides objective hepatic reserve estimation across each BCLC stage of hepatocellular carcinoma 91
PD-1/PD-L1 checkpoint inhibitors during late stages of life: an ad-hoc analysis from a large multicenter cohort 90
Clinical portrait of the SARS-CoV-2 epidemic in European cancer patients 89
Time-Dependent COVID-19 Mortality in Patients with Cancer: An Updated Analysis of the OnCovid Registry 88
L’impatto del Long COVID è stato minore nella terza ondata della pandemia rispetto alla prima ondata in una popolazione italiana di 324 pazienti. 85
Systemic pro-inflammatory response identifies patients with cancer with adverse outcomes from SARS-CoV-2 infection: The OnCovid Inflammatory Score 82
Prognostic sub-classification of intermediate-stage hepatocellular carcinoma: a multicenter cohort study with propensity score analysis. 79
HBV AND LYMPHOMAGENESIS: NOVEL INSIGHTS INTO AN OCCULT RELATIONSHIP 78
Integrated use of PD-1 inhibition and transarterial chemoembolization for hepatocellular carcinoma: evaluation of safety and efficacy in a retrospective, propensity score-matched study 76
Clinical implications of heterogeneity in PD-L1 immunohistochemical detection in hepatocellular carcinoma: the Blueprint-HCC study 76
Determinants of enhanced vulnerability to coronavirus disease 2019 in UK patients with cancer: a European study 76
Treatment Stage Migration Maximizes Survival Outcomes in Patients with Hepatocellular Carcinoma Treated with Sorafenib: An Observational Study 74
Post-progression outcomes of NSCLC patients with PD-L1 expression ≥ 50% receiving first-line single-agent pembrolizumab in a large multicentre real-world study 73
Predictive ability of a drug-based score in patients with advanced non–small-cell lung cancer receiving first-line immunotherapy 73
Hepatitis B virus and lymphomagenesis: novel insights into an occult relationship 72
The albumin–bilirubin grade improves hepatic reserve estimation post-sorafenib failure: implications for drug development 71
COVID-19 in breast cancer patients: a subanalysis of the OnCovid registry 69
Hepatic decompensation is the major driver of mortality in hepatocellular carcinoma patients treated with atezolizumab plus bevacizumab: The impact of successful antiviral treatment 67
T-cell mediated responses against alpha-foetoprotein in hepatocellular carcinoma: Relationship with hepatitis C virus infection, tumour phenotype and patients’ survival 65
Anthracyclines Strike Back: Rediscovering Non-Pegylated Liposomal Doxorubicin in Current Therapeutic Scenarios of Breast Cancer 63
Activation and transcriptional profile of monocytes and CD8+ T cells are altered in checkpoint inhibitor-related hepatitis 62
Impact of body mass index in patients receiving atezolizumab plus bevacizumab for hepatocellular carcinoma 61
Antibiotic therapy and outcome from immune-checkpoint inhibitors 61
Codon-specific KRAS mutations predict survival benefit of trifluridine/tipiracil in metastatic colorectal cancer 60
Back from the brink: EGFR inhibition in gastroesophageal cancer 60
Impact of age on sorafenib outcomes in hepatocellular carcinoma: an international cohort study 60
Advanced age influences the dynamic changes in circulating C-reactive protein following injury 60
Differential influence of antibiotic therapy and other medications on oncological outcomes of patients with non-small cell lung cancer treated with first-line pembrolizumab versus cytotoxic chemotherapy 60
Immune checkpoint inhibitor therapy and outcomes from SARS-CoV-2 infection in patients with cancer: a joint analysis of OnCovid and ESMO-CoCARE registries 59
ALBI grade: Evidence for an improved model for liver functional estimation in patients with hepatocellular carcinoma 59
A novel, externally validated inflammation-based prognostic algorithm in hepatocellular carcinoma: The prognostic nutritional index (PNI) 59
Outcomes of the SARS-CoV-2 omicron (B.1.1.529) variant outbreak among vaccinated and unvaccinated patients with cancer in Europe: results from the retrospective, multicentre, OnCovid registry study 59
High familial burden of cancer correlates with improved outcome from immunotherapy in patients with NSCLC independent of somatic DNA damage response gene status 58
SARS-CoV-2 omicron (B.1.1.529)-related COVID-19 sequelae in vaccinated and unvaccinated patients with cancer: results from the OnCovid registry 58
Stereotactic Body Radiation Therapy as an Alternative Treatment for Patients with Hepatocellular Carcinoma Compared to Sorafenib: A Propensity Score Analysis 58
The albumin-bilirubin grade uncovers the prognostic relationship between hepatic reserve and immune dysfunction in HIV-associated hepatocellular carcinoma 57
Knowledge and attitudes of Italian medical oncologists and palliative care physicians toward medical use of cannabis in cancer care: a national survey 57
Antibiotic-dependent effect of probiotics in patients with non-small cell lung cancer treated with PD-1 checkpoint blockade 56
INTERLEUKIN-6 POLYMORPHISMS AND GENDER: RELATIONSHIP WITH THE OCCURRENCE OF HEPATOCELLULAR CARCINOMA IN PATIENTS WITH END-STAGE LIVER DISEASE 56
The Kings Score refines prognostic prediction in hepatocellular carcinoma: a novel application 56
Acceleration of interstitial lung disease induced by raltitrexed 56
Clinicopathologic and Genomic Factors Impacting Efficacy of First-Line Chemoimmunotherapy in Advanced NSCLC 55
A Pilot Randomized, Placebo Controlled, Double Blind Phase I Trial of the Novel SIRT1 Activator SRT2104 in Elderly Volunteers 55
Antibiotic-exposed patients with non-small-cell lung cancer preserve efficacy outcomes following first-line chemo-immunotherapy 55
GENDER-RELATED DISTRIBUTION OF THE INTERLEUKIN-1BETA AND INTERLEUKIN-1 RECEPTOR ANTAGONIST GENE POLYMORPHISMS IN PATIENTS WITH END-STAGE LIVER DISEASE 54
Assessing the impact of COVID-19 on liver cancer management (CERO-19) 54
Phenotypic Characteristics of the Tumour Microenvironment in Primary and Secondary Hepatocellular Carcinoma 54
Atezolizumab plus bevacizumab versus lenvatinib or sorafenib in non-viral unresectable hepatocellular carcinoma: an international propensity score matching analysis 53
Immune checkpoint inhibitors in hepatocellular carcinoma: emerging challenges in clinical practice 53
The expression of Axl receptor tyrosine kinase influences the tumour phenotype and clinical outcome of patients with malignant pleural mesothelioma 53
Response to letter entitled: Re: Predictive ability of a drug-based score in advanced non-small cell lung cancer patients receiving first-line immunotherapy 53
Predictive biomarkers of response to immune checkpoint inhibitors in hepatocellular carcinoma 53
COVID-19 Sequelae and the Host Proinflammatory Response: An Analysis From the OnCovid Registry 53
Vaccination against SARS-CoV-2 protects from morbidity, mortality and sequelae from COVID19 in patients with cancer 52
An inflammation based score can optimize the selection of patients with advanced cancer considered for early phase clinical trials 52
A New Prognostic Model in Patients with Advanced Urothelial Carcinoma Treated with First-line Immune Checkpoint Inhibitors 52
Prognostic effect of body mass index in patients with advanced NSCLC treated with chemoimmunotherapy combinations 52
Reliability and reproducibility of the edmondson grading of hepatocellular carcinoma using paired core biopsy and surgical resection specimens 51
Alterations of choline phospholipid metabolism in endometrial cancer are caused by choline kinase alpha overexpression and a hyperactivated deacylation pathway 51
Programmed cell death ligands expression drives immune tolerogenesis across the diverse subtypes of neuroendocrine tumours 51
Immunotherapies for hepatocellular carcinoma 50
Mechanisms of Resistance to Immunotherapy in Hepatocellular Carcinoma 50
Outcomes of beta blocker use in advanced hepatocellular carcinoma treated with immune checkpoint inhibitors 50
Isogeneic comparison of primary and metastatic lung cancer identifies CX3CR1 as a molecular determinant of site-specific metastatic diffusion 50
NASH limits anti-tumour surveillance in immunotherapy-treated HCC 50
A novel and validated prognostic index in hepatocellular carcinoma: The inflammation based index (IBI) 50
Association of prior antibiotic treatment with survival and response to immune checkpoint inhibitor therapy in patients with cancer 50
Biliary tract cancers: Molecular heterogeneity and new treatment options 50
Antibiotic Treatment and Immune Checkpoint Inhibitor Therapy in Patients with Cancer - Reply 50
Breaking the Child-Pugh Dogma in Hepatocellular Carcinoma 49
An expression signature of the angiogenic response in gastrointestinal neuroendocrine tumours: Correlation with tumour phenotype and survival outcomes 49
Neutrophil-to-Lymphocyte and Platelet-to-Lymphocyte Ratios as Prognostic Biomarkers in Unresectable Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab 48
Preliminary qualification of a novel, hypoxic-based radiologic signature for trans-arterial chemoembolization in hepatocellular carcinoma 48
Prediction of Survival Among Patients Receiving Transarterial Chemoembolization for Hepatocellular Carcinoma: A Response-Based Approach 48
International Liver Cancer Association (ILCA) White Paper on Biomarker Development for Hepatocellular Carcinoma 48
Safety and Activity of Immune Checkpoint Inhibitors in People Living With HIV and Cancer: A Real-World Report From the Cancer Therapy Using Checkpoint Inhibitors in People Living With HIV-International (CATCH-IT) Consortium 47
Novel immunotherapy combinations in clinical trials for hepatocellular carcinoma: will they shape the future treatment landscape? 47
Pandemic Phase-Adjusted Analysis of COVID-19 Outcomes Reveals Reduced Intrinsic Vulnerability and Substantial Vaccine Protection From Severe Acute Respiratory Syndrome Coronavirus 2 in Patients With Breast Cancer 47
Impact of older age in patients receiving atezolizumab and bevacizumab for hepatocellular carcinoma 47
Tissue biomarkers of prognostic significance in hepatocellular carcinoma. 47
Personalised management of patients with hepatocellular carcinoma: a multiparametric therapeutic hierarchy concept 46
Efficacy and safety of immune checkpoint inhibitor rechallenge in individuals with hepatocellular carcinoma 46
PETAL protocol: A phase Ib study of pembrolizumab after transarterial chemoembolization in hepatocellular carcinoma 46
Early Antibiotic Exposure Is Not Detrimental to Therapeutic Effect from Immunotherapy in Hepatocellular Carcinoma 46
Preliminary evidence of safety and tolerability of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma and Child-Pugh A and B cirrhosis: A real-world study 46
Concomitant type 2 diabetes mellitus (T2DM) in metastatic melanoma patients could be related to lower level of LAG-3: a transcriptomic analysis of a retrospective cohort 46
Chronic Hepatitis C Infection Treated with Direct-Acting Antiviral Agents and Occurrence/Recurrence of Hepatocellular Carcinoma: Does It Still Matter? 45
Previous immune checkpoint inhibitor therapy is associated with decreased COVID-19-related hospitalizations and complications in patients with cancer: Results of a propensity-matched analysis of the OnCovid registry 45
Early hepatic decompensation identifies patients with hepatocellular carcinoma treated with Atezolizumab plus Bevacizumab or Sorafenib at highest risk of death 45
Totale 6.361
Salva come PNG Salva come JPEG
Categoria #
all - tutte 90.813
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 90.813
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021318 0 0 0 0 0 5 28 5 26 113 128 13
2021/2022799 27 2 174 71 46 6 24 21 68 63 126 171
2022/20231.810 217 43 77 6 51 106 43 79 1.132 5 27 24
2023/20241.084 136 46 82 33 209 14 222 15 4 39 56 228
2024/20253.885 45 26 204 19 36 331 391 346 904 590 261 732
2025/20264.209 548 499 678 1.060 1.303 121 0 0 0 0 0 0
Totale 12.617